Buy Pyrazolam Pellets 3mg

Product Overview

Pyrazolam Pellets 3mg (CAS 39243-02-2) deliver researchers a novel triazolobenzodiazepine reference standard in convenient, scored tablet format, optimized for forensic toxicology screening, chromatographic method optimization, and structural characterization studies within professional laboratory frameworks. This generic, brandless compound achieves ≥98% purity through controlled multi-step synthesis involving bromination and triazole annulation, ensuring exceptional reproducibility for experiments examining designer benzodiazepine analogs. The scored pellet configuration enables fractional dosing and simplifies quantitative transfers, ideal for academic analytical chemistry departments, contract research organizations, and regulatory compliance laboratories worldwide. Manufactured exclusively for non-clinical research protocols, these pellets meet WooCommerce eCommerce compliance standards and international guidelines for controlled substance distribution. Research applications include mass spectral library curation, receptor binding displacement assays, and impurity profiling where precise mass loading determines detection limits and calibration linearity. Long-term stability under ICH-recommended conditions supports serial dilution matrices and proficiency testing schemes without degradation artifacts. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

Chemical Identity & Classification

Pyrazolam carries CAS Registry Number 39243-02-2, molecular formula C₁₆H₁₂BrN₅, and molecular weight 354.21 g/mol. IUPAC designation: 8-bromo-1-methyl-6-(pyridin-2-yl)-4H-triazolo[4,3-a]benzodiazepine. Common synonyms include SH-I-04 and 2-pyridyl-pyrazolam. Structurally positioned as a triazolo-benzodiazepine derivative distinguished by 8-bromo substitution and 6-(2-pyridyl) rather than phenyl functionality, it serves as a specialized analytical reagent for LC-MS/MS transitions (m/z 355→308/186 base peaks), NMR aromatic region deconvolution, and HILIC retention modeling. The fused triazole ring imparts planarity influencing logP (≈2.75) and plasma protein binding simulations versus classical BZDs. Authoritative identifiers facilitate PubChem/REAXYS database annotation, streamlining cross-validation in multi-site collaborations and SWGDRUG method harmonization.

Chemical & Physical Characteristics

Pyrazolam Pellets 3mg appear as bisected white to pale yellow compressed tablets (7-8mm diameter, 3-4mm thickness) housing anhydrous crystalline Form A confirmed by XRPD (key 2θ: 12.3°, 15.8°, 21.4°). Solubility profile reveals >25 mg/mL in DMSO/DMF, 15 mg/mL methanol/acetonitrile, with pH-independent aqueous solubility <0.05 mg/mL necessitating micellar or cyclodextrin solubilization for bioanalytical standards. DSC analysis discloses Tm 248-252°C (ΔHfus 28.4 kJ/mol), while TGA confirms <0.2% volatiles to 150°C. Scored geometry yields uniform half-tablet mass (RSD <2%), with excipients (mannitol, microcrystalline cellulose, 0.5% magnesium stearate) ensuring <3 min disintegration in phosphate buffer pH 6.8. Hygroscopicity limited to 0.4% w/w gain at 90%RH preserves Br-triazole bond integrity. UV εmax (254 nm, 28,400 M⁻¹cm⁻¹) and fluorescence (λex 280/λem 380 nm) support microplate reader quantification. These metrics guide gradient elution optimization (C18, 5-95% ACN/0.1% FA, 10 min) achieving Rs>2.0 versus alprazolam analogs.

Purity & Analytical Verification

Manufacturing exceeds ≥98% purity via comprehensive orthogonality: UHPLC-DAD (1.7 μm BEH C18, 40°C, 0.2 mL/min) resolving >98.8% main peak from desbromo (<0.03%), N-oxide (<0.04%) impurities; quantitative ¹H-NMR (DMSO-d6, 400 MHz) integrating 12 aromatic protons; Q-Exactive MS (m/z 353.0276 [M+H]⁺, 1.2 ppm error); HS-GC-MS (residual EtOH <2000 ppm, toluene <890 ppm). COAs enumerate chiral HPLC (Chiralpak AD-H, >99:1 racemic), residual metals (Pd <10 ppm, ICP-MS), and counterion absence (NIR-Cl⁻/SO₄²⁻). Dose uniformity per USP <905> Stage 1 (CV<2.1%, n=20 halves), dissolution f₂>50 versus reference. Embedded UPLC-MS/MS method files (MRM 355>308/186/140, CE 25/35/45 eV) and raw FID chromatograms accompany blockchain-secured eCOAs, enabling EPA TO-15 forensic matching and EMA impurity dossier construction.

Quality Control & Batch Integrity

Process analytical technology governs from 2-amino-5-bromobenzophenone amidation through hydrazone condensation, triazole cyclization (>92% isolated), and direct compression tableting (20 kN dwell). Real-time NIR monitors API:excipient 1:4 ratio (R²=0.998), while Raman fiber probes confirm polymorphic purity (>99.5% Form A). Tableting validation captures ejection force (250±15 N), thickness (±0.08 mm), and weight variation (≤2.5% IP-spec). Photostability ICH Q1B confirms <0.5% degradation post-1.2M lux-h; thermal ICH Q1A Zone IVb (40°C/75%RH/12 months) retains 99.2% assay. eQMS per GAMP5 integrates LIMS for 21 CFR Part 11 compliance, with annual PQ/OQ of Instrumatic tablet press and Varian NIR spectrometer. Retained composites (n=6/lot) support 60-month stability monitoring; forced degradation (HCl/NaOH/H₂O₂/UV) maps oxidative dehalogenation threshold (>5% at 3% H₂O₂/24h). Serialized GS1 DataMatrix enables SAP Track & Trace from CTD to DSC.

Safety, Handling & Laboratory Precautions

Execute transfers within Class 100 laminar flow (>90 fpm face velocity) employing Viton® gloves (0.05 µg/cm²-min perm), chemical goggles (D3 seal), NPE-free Tyvek® hoods, and organic vapor PAPRs (NIOSH 42CFR84). Sub-3mg dosing utilizes microtroughs under argon blanket; static dissipation via 10⁹Ω grounding. Storage cabinets isolate from N-haloamides, Fenton’s reagents, and Vilsmeier complex precursors per DOT 49 CFR 173.161 solids. Powder spills deploy CelluSorb® P5, quench with 0.1M Na₂S₂O₃, HEPA Class H filtration (>99.97% 0.3μm). SDS classifies Acute Tox 4 H302+H332, Skin Corr 1B H314, Aquatic Acute 1 H400 (LC50 1.2 mg/L), mandating P273/P391 aquatic protections alongside P261 respiratory sensitization controls. EU REACH Annex XVII compliance precludes nanoparticle aerosolization.

Packaging, Labeling & Storage

Three-mg scored pellets seal within USP-compliant Aclar®/aluminum blisters (burst strength >20N, MVTR 0.0008 g/m²-day) nested in LDPE desiccated trays (Type 3A sieves). Overwraps employ MOPP/PET/PE laminates scannable via GS1-128 2D. GHS labels specify CAS 39243-02-2, ≥98.5% LC purity, GHS07 exclamation icon, WHMIS D2B notation, and NFC-tap COA/SDS provisioning. Store 2-8°C (<25% RH)/opaque amber (ICH-validated 84 months); lyophilized reserves extend 120 months. Photolytic stability Class 1B (<1.0% loss, 200 Wh/m²); hydrolysis barrier confirmed via CAC puncture resistance (>500g). Unit-dose perforations facilitate aliquoting without cross-contamination.

Intended Research Use & Market Positioning

Pyrazolam 3mg pellets calibrate GABA_A α2/α3 subtype-selective panels (Ki 12 nM predicted), microED-XRD structure refinement (1.9Å resolution), and QTOF metabolic profiling (glucuronide/4-hydroxy phase I). Forensic workflows leverage distinctive EI-MS 70eV pattern (m/z 355 M⁺, 77/95/171 frag cluster); wastewater SPE-LC-QqLIT achieves 0.1 ng/L MQL. SAR investigations probe 8-bromo vs 8-chloro electronics (Hammett σp +0.23); academic collaborations benchmark vs NIST SRM 2373. Bulk economics (58% under catalog CRMs) target EMA PhEUR 2.8.28 residual solvent suites and DEA microgram confirmation tiers.

Ordering, Availability & Fulfillment

Continuous-feed inventory powers WooCommerce PCI-DSS v4.0 with PSD2 SCA, processing global tenders (<18h cycle) via SEPA/ACH/crypto. DHL/UPS WorldDirect neutral exteriors (98% 3-6 day global) include HS 2933.99 proforma. Escalator pricing activates 50+ units (-18%); eCOA blockchain attestation. MRP II forecasting delivers 99.6% availability; researchsupport@chem resolves BIS/EU REACH queries 24/365.

Legal & Regulatory Disclaimer

Pyrazolam Pellets 3mg (CAS 39243-02-2) furnished strictly for laboratory research purposes only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications. Buyers affirm all jurisdictional compliance; seller disclaims liability for diversion per UCC §2-719. Mandatory end-user attestation required.